Meddenovo Drug Design is honored to be named a laureate of the i-Lab Innovation Competition 2025, the French government’s flagship program supporting high-impact deep tech start-ups emerging from strong scientific foundations.

Managed on behalf of the French government by Bpifrance and supported under the France 2030 investment plan, i-Lab identifies breakthrough innovation projects grounded in scientific excellence and accelerates their development toward commercialization.

More than an award, i-Lab is widely recognized within the French deep tech ecosystem as a key marker of technological strength and long-term potential, acknowledged by both public institutions and private investors. Since its creation in 1999, the competition has supported thousands of innovation-driven companies and continues to play a central role in shaping the next generation of European technology leaders.

Being selected as an i-Lab laureate reinforces Meddenovo’s positioning as a deep tech company operating at the intersection of advanced computational science, AI-driven molecular design, and next-generation drug discovery. Through this recognition, Meddenovo joins a national network of pioneering companies benefiting from increased visibility, expert support, and access to non-dilutive financing instruments designed to accelerate the development of disruptive technologies in strategic sectors.

With this achievement, Meddenovo has now secured €700K in non-dilutive funding since its creation in 2023, further strengthening its capacity to accelerate innovation in cyclic peptide and complex modality design through its AI-powered Mexa platform.